Clinical Trials Directory

Trials / Unknown

UnknownNCT04499365

68Ga-FAPI PET/CT in Patients With Various Types of Cancer

68Ga-DOTA/NOTA-FAPI-04 PET/CT in Patients With Various Types of Cancer

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
500 (estimated)
Sponsor
First Affiliated Hospital of Fujian Medical University · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

To evaluate the potential usefulness of 68Ga-DOTA/NOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.

Detailed description

Subjects with various types of cancer underwent 68Ga-DOTA/NOTA-FAPI-04 PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga-DOTA/NOTA-FAPI-04 PET/CT were calculated.

Conditions

Interventions

TypeNameDescription
DRUG68Ga-DOTA/NOTA-FAPI-04Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
DIAGNOSTIC_TESTPET/CT scanPET/CT scan

Timeline

Start date
2020-08-15
Primary completion
2023-12-30
Completion
2023-12-30
First posted
2020-08-05
Last updated
2020-09-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04499365. Inclusion in this directory is not an endorsement.